logo

For the Inventor, By the Inventor

Castres, France

Bernard Vacher

USPTO Granted Patents = 22 


 

Average Co-Inventor Count = 3.2

ph-index = 3

Forward Citations = 45(Granted Patents)


Company Filing History:

goldMedal22 out of 266 
 
Pierre Fabre Medicament
 patents

Years Active: 2000-2017

Loading Chart...
Loading Chart...
Loading Chart...
22 patents (USPTO):Explore Patents
1. 9687459 - Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs (2017-06-27),
2. 9603835 - Use of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine for treating cancer and in particular for preventing and/or treating cancer metastases (2017-03-28),
3. 9469601 - Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs (2016-10-18),
4. 9433603 - Use of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine for preventing and/or treating cardiotoxic effects caused by chemotherapy and/or radiation (2016-09-06),
5. 8669250 - Derivatives of aryl-{4-halogeno-4-[aminomethyl]-piperidin-1-yl}-methanone, their method of preparation and their use as medicinal products (2014-03-11),
6. 8609694 - Use of pyridin-2-yl-methylamine derivatives for the production of a medicament for the treatment of chronic pain symptoms of neuropathological or psychogenic origin (2013-12-17),
7. 8455550 - Derivatives of aminocyclobutane or aminocyclobutene, their method of preparation and their use as medical products (2013-06-04),
8. 8188126 - Imidazolic compounds and use thereof as alpha-2 adrenergic receptors (2012-05-29),
9. 8106074 - Pyridin-2-yl-methylamine derivatives for treating opiate dependence (2012-01-31),
10. 7982054 - Process for the synthesis of N-[3-[(2-methoxyphenyl] sulfanyl] -2-methylpropyl] -3,4-dihydro-2H-1,5-benzoxathiepin-3-amine (2011-07-19),
11. 7902381 - Synthesising method and benzoxathiepine intermediates (2011-03-08),
12. 7776901 - Imidazolic compounds and use thereof as alpha-2 adrenergic receptors (2010-08-17),
13. 7547700 - Aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments (2009-06-16),
14. 7235568 - 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia (2007-06-26),
15. 7220866 - Imidazolic compounds and use thereof as alpha-2-adrenergic receptors (2007-05-22),

Title: The Innovative Contributions of Bernard Vacher in Pharmaceutical Patents

Introduction: Bernard Vacher, an esteemed inventor based in Castres, France, has made significant advancements in the pharmaceutical industry with over 22 patents to his name. His innovative work primarily focuses on the development of aminocyclobutane derivatives and their applications in human therapy.

Latest Patents: Among his latest patents, Vacher's work on aminocyclobutane derivatives stands out. These derivatives serve as NMDA receptor antagonists and hold promise in the treatment of various medical conditions. His patent details methods for preparing these compounds, which conform to a specified general formula. Additionally, Vacher has developed a specific application of the compound 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine for treating cancer. This innovation particularly aims to prevent and treat cancer metastases, making a notable impact in the fight against cancer.

Career Highlights: Bernard Vacher's career is marked by his association with Pierre Fabre Medicament, a leading company in the pharmaceutical sector. Through his work, he has not only contributed to the advancement of medical treatments but has also established a reputation as a prominent inventor in his field.

Collaborations: Vacher's innovative journey includes collaborations with notable colleagues such as Bernard Bonnaud and Wouter Koek. These partnerships have fostered a robust environment for research and development, further enhancing the impact of his inventions.

Conclusion: Bernard Vacher’s contributions to pharmaceutical patents represent a significant leap forward in medical innovation. With a strong portfolio of patents and collaborations, he continues to shape the future of drug development, making strides that benefit human health and therapy. His work remains an inspiration in the realm of scientific exploration and innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…